Brief Report on Organon & Co. Stock

Shares of Health Care sector company Organon & Co. moved 0.9% today, and are now trading at a price of $20.6. The mid-cap stock's daily volume was 95,731 compared to its average volume of 2,030,196. The S&P 500 index returned a 1.0% performance.

Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. The company is based in Jersey City and has 10,000 full time employees. Its market capitalization is $5,254,277,120. Organon & Co. currently offers its equity investors a dividend that yields 5.5% per year.

7 analysts are following Organon & Co. and have set target prices ranging from $23.0 to $43.0 per share. On average, they have given the company a rating of hold. At today's prices, OGN is trading -33.85% away from its average analyst target price of $31.14 per share.

Over the last year, OGN shares have gone down by -38.4%, which represents a difference of -55.0% when compared to the S&P 500. The stock's 52 week high is $36.08 per share and its 52 week low is $18.87. Although Organon & Co.'s average free cash flow over the last 4 years has been $1.75 Billion, they have been decreasing at an average rate of -36.6%. For this reason, investors may continue to shun the stock.

Date Reported Cash Flow from Operations ($ k) Capital expenditures ($ k) Free Cashflow ($ k) YoY Growth (%)
2022-12-31 858,000 -427,000 431,000 -78.12
2021-12-31 2,458,000 -488,000 1,970,000 3.2
2020-12-31 2,187,000 -278,000 1,909,000 -28.64
2019-12-31 2,767,000 -92,000 2,675,000 n/a
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.